Insider trade

Director sold ~$147K of KRYS shares in the open market

Traded Jun 4, 2026 · Filed Jun 5, 2026

Why it stands out

A Krystal Biotech director sold $147K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$146,815

Shares × reported transaction price

Timing vs results

107 days after results of Feb 17, 2026, 60 days before results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+7.6%	+2.1%	+5.5%
30 days	+24.4%	+0.8%	+23.6%
90 days	+16.4%	+3.6%	+12.8%

Past results only. Not a forecast.

The transaction was executed in multiple trades ranging from $305.19 to $306.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.